UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2013
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At August 5, 2013, 6,620,299,870 shares of the issuer s voting common stock were outstanding.
Table of Contents
FORM 10-Q
For the Quarterly Period Ended
June 30, 2013
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended June 30, 2013 and July 1, 2012
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2013 and July 1, 2012
Condensed Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2013 and July 1, 2012
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
49
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
50
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
93
Item 4.
Controls and Procedures
94
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
95
Item 1A.
Risk Factors
95
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
96
Item 3.
Defaults Upon Senior Securities
96
Item 4.
Mine Safety Disclosures
96
Item 5.
Other Information
96
Item 6.
Exhibits
97
Signature
98
Table of Contents
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
June 30,
2013
July 1,
2012
June 30,
2013
July 1,
2012
Revenues
12,973
13,968
25,383
27,813
Costs and expenses:
Cost of sales(a)
2,242
2,376
4,505
4,759
Selling, informational and administrative expenses(a)
3,591
3,665
6,808
7,343
Research and development expenses(a)
1,530
1,600
3,240
3,574
Amortization of intangible assets
1,140
1,275
2,359
2,678
Restructuring charges and certain acquisition-related costs
183
184
314
773
Other (income)/deductions net
(1,070
688
(925
2,327
Income from continuing operations before provision for taxes on income
5,357
4,180
9,082
6,359
Provision for taxes on income
1,782
1,180
2,891
1,805
Income from continuing operations
3,575
3,000
6,191
4,554
Discontinued operations:
Income from discontinued operations net of tax
141
260
290
509
Gain on disposal of discontinued operations net of tax
10,418
10,418
Discontinued operations net of tax
10,559
260
10,708
509
Net income before allocation to noncontrolling interests
14,134
3,260
16,899
5,063
Less: Net income attributable to noncontrolling interests
39
54
16
Net income attributable to Pfizer Inc.
14,095
3,253
16,845
5,047
Earnings per common share basic(b):
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.51
0.40
0.87
0.60
Discontinued operations net of tax
1.50
0.03
1.50
0.07
Net income attributable to Pfizer Inc. common shareholders
2.00
0.44
2.37
0.67
Earnings per common share diluted(b):
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.50
0.40
0.86
0.60
Discontinued operations net of tax
1.48
0.03
1.49
0.07
Net income attributable to Pfizer Inc. common shareholders
1.98
0.43
2.34
0.67
Weighted-average shares basic
7,042
7,476
7,115
7,506
Weighted-average shares diluted
7,117
7,537
7,185
7,570
Cash dividends paid per common share
0.24
0.22
0.48
0.44
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.
(b)
EPS amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
June 30,
2013
July 1,
2012
June 30,
2013
July 1,
2012
Net income before allocation to noncontrolling interests
14,134
3,260
16,899
5,063
Foreign currency translation adjustments
(755
(1,981
(1,047
(1,718
Reclassification adjustments(a)
171
171
(584
(1,981
(876
(1,718
Unrealized holding gains/(losses) on derivative financial instruments
263
(657
(154
(230
Reclassification adjustments for realized (gains)/losses(b)
(132
427
249
127
131
(230
95
(103
Unrealized holding gains on available-for-sale securities
88
12
99
92
Reclassification adjustments for realized (gains)/losses(b)
(18
16
(31
33
70
28
68
125
Benefit plans: actuarial gains/(losses)
29
(505
47
(504
Reclassification adjustments related to amortization(c)
150
113
301
229
Reclassification adjustments related to curtailments/settlements, net(c)
34
(8
93
112
Foreign currency translation adjustments and other
43
39
140
55
256
(361
581
(108
Benefit plans: prior service (costs)/credits and other
26
26
Reclassification adjustments related to amortization(c)
(13
(17
(29
(34
Reclassification adjustments related to curtailments/settlements, net(c)
(73
(9
(82
Other
(4
(6
(4
(17
(64
(41
(94
Other comprehensive loss, before tax
(144
(2,608
(173
(1,898
Tax provision/(benefit) on other comprehensive loss(d)
187
(205
363
(1
Other comprehensive loss before allocation to noncontrolling interests
(331
(2,403
(536
(1,897
Comprehensive income before allocation to noncontrolling interests
13,803
857
16,363
3,166
Less: Comprehensive income/(loss) attributable to noncontrolling interests
18
(10
30
(2
Comprehensive income attributable to Pfizer Inc.
13,785
867
16,333
3,168
(a)
Primarily reclassified into Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income.
(b)
Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.
(c)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(d)
See Note 5C. Tax Matters: Taxes on Items of Other Comprehensive Loss.
See Notes to Condensed Consolidated Financial Statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
June 30,
2013
December 31,
2012
(Unaudited)
Assets
Cash and cash equivalents
2,436
10,081
Short-term investments
31,275
22,318
Accounts receivable, less allowance for doubtful accounts
11,523
11,456
Inventories
6,282
6,076
Taxes and other current assets
9,819
8,956
Assets of discontinued operations and other assets held for sale
100
5,944
Total current assets
61,435
64,831
Long-term investments
16,107
14,149
Property, plant and equipment, less accumulated depreciation
12,443
13,213
Goodwill
42,431
43,661
Identifiable intangible assets, less accumulated amortization
41,776
45,146
Taxes and other noncurrent assets
5,143
4,798
Total assets
179,335
185,798
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
5,214
6,424
Accounts payable
1,978
2,921
Dividends payable
1,685
1,733
Income taxes payable
904
979
Accrued compensation and related items
1,430
1,875
Other current liabilities
12,218
13,812
Liabilities of discontinued operations
21
1,442
Total current liabilities
23,450
29,186
Long-term debt
31,532
31,036
Pension benefit obligations
7,534
7,782
Postretirement benefit obligations
3,454
3,491
Noncurrent deferred tax liabilities
22,338
21,193
Other taxes payable
6,819
6,581
Other noncurrent liabilities
5,231
4,851
Total liabilities
100,358
104,120
Commitments and Contingencies
Preferred stock
36
39
Common stock
451
448
Additional paid-in capital
76,412
72,608
Treasury stock
(59,515
(40,122
Retained earnings
67,628
54,240
Accumulated other comprehensive loss
(6,465
(5,953
Total Pfizer Inc. shareholders equity
78,547
81,260
Equity attributable to noncontrolling interests
430
418
Total equity
78,977
81,678
Total liabilities and equity
179,335
185,798
See Notes to Condensed Consolidated Financial Statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(MILLIONS OF DOLLARS)
June 30,
2013
July 1,
2012
Operating Activities
Net income before allocation to noncontrolling interests
16,899
5,063
Adjustments to reconcile net income before allocation to noncontrolling interests to net
cash provided by operating activities:
Depreciation and amortization
3,297
3,892
Share-based compensation expense
292
247
Gain associated with the transfer of certain product rights to an equity-method investment
(459
Asset write-offs and impairment charges
648
758
Gain on disposal of discontinued operations
(10,539
Deferred taxes from continuing operations
1,254
(126
Deferred taxes from discontinued operations
(19
20
Benefit plan contributions (in excess of)/less than expense
164
(20
Other non-cash adjustments, net
(192
(114
Other changes in assets and liabilities, net of acquisitions and divestitures
(5,274
(2,925
Net cash provided by operating activities
6,071
6,795
Investing Activities
Purchases of property, plant and equipment
(511
(548
Purchases of short-term investments
(21,663
(10,395
Proceeds from redemptions and sales of short-term investments
14,502
14,357
Net purchases of short-term investments with original maturities of 90 days or less
(401
(999
Purchases of long-term investments
(5,233
(2,317
Proceeds from redemptions and sales of long-term investments
3,194
304
Acquisitions, net of cash acquired
(15
(782
Other investing activities
33
(56
Net cash used in investing activities
(10,094
(436
Financing Activities
Proceeds from short-term borrowings
2,334
3,764
Principal payments on short-term borrowings
(2,333
(3,799
Net proceeds from/(payments on) short-term borrowings with original maturities of 90 days or less
2,251
(349
Proceeds from issuance of long-term debt(a)
6,618
Principal payments on long-term debt
(2,394
(7
Purchases of common stock
(7,889
(2,999
Cash dividends paid
(3,436
(3,283
Proceeds from exercise of stock options and other financing activities
1,249
198
Net cash used in financing activities
(3,600
(6,475
Effect of exchange-rate changes on cash and cash equivalents
(22
(35
Net decrease in cash and cash equivalents
(7,645
(151
Cash and cash equivalents, beginning
10,081
3,182
Cash and cash equivalents, end
2,436
3,031
Supplemental Cash Flow Information
Non-cash transactions:
Sale of Zoetis (our Animal Health business) for Pfizer common stock(b)
11,408
Exchange of Zoetis common stock for the retirement of Pfizer commercial paper issued in 2013(b)
2,479
Exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012(b)
992
Transfer of certain product rights to an equity-method investment(c)
1,233
Cash paid during the period for:
Income taxes
1,305
1,127
Interest
1,103
1,194
(a)
Includes $2.6 billion from the issuance of senior notes by Zoetis, our former Animal Health subsidiary, net of the non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Divestitures.
(b)
See Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Divestitures.
(c)
See Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment.
See Notes to Condensed Consolidated Financial Statements.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.
Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and six months ended May 26, 2013 and May 27, 2012.
On June 24, 2013, we completed the full disposition of our Animal Health business (Zoetis), and recognized a gain of approximately $10.4 billion, net of tax, related to the disposal of this business in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended June 30, 2013. The operating results of this business are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. In addition, in the condensed consolidated balance sheet as of December 31, 2012, the assets and liabilities associated with this business are classified as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate. Prior period financial statements have been restated. For additional information, see Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Divestitures.
On November 30, 2012, we completed the sale of our Nutrition business to Nestl . The operating results of this business are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended July 1, 2012. For additional information, see Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Divestitures.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and results of operations.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2012 Annual Report on Form 10-K/A.
B. Adoption of New Accounting Standards
There were no new accounting and disclosure standards adopted in 2013.
C. Fair Value
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 2. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment
A. Acquisitions
NextWave Pharmaceuticals, Inc.
In the first quarter of 2013, we finalized the allocation of the consideration transferred to the assets acquired and the liabilities assumed in the acquisition of NextWave Pharmaceuticals Incorporated (NextWave), completed on November 27, 2012. The total consideration for the acquisition was approximately $442 million, and we recorded $519 million in Identifiable intangible assets, consisting of $474 million in Developed technology rights and $45 million in In-process research and development; $166 million in net deferred tax liabilities; and $89 million in Goodwill.
Alacer Corp.
On February 26, 2012, we completed our acquisition of Alacer Corp., a company that manufactures, markets and distributes Emergen-C, a line of effervescent, powdered drink mix vitamin supplements that is the largest-selling branded vitamin C line in the U.S. In connection with this Consumer Healthcare acquisition, we recorded $181 million in Identifiable intangible assets, consisting primarily of the Emergen-C indefinite-lived brand; $69 million in net deferred tax liabilities; and $192 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has been finalized.
Ferrosan Holding A/S
On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan Holding A/S (Ferrosan), a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. This acquisition is reflected in our condensed consolidated financial statements beginning in the first fiscal quarter of 2012. Our acquisition of Ferrosan s consumer healthcare business increases our presence in dietary supplements with a new set of brands and pipeline products. Also, we believe that the acquisition allows us to expand the marketing of Ferrosan s brands through Pfizer s global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate, in Ferrosan s key markets. In connection with this Consumer Healthcare acquisition, we recorded $362 million in Identifiable intangible assets, consisting of indefinite-lived and finite-lived brands; $94 million in net deferred tax liabilities; and $322 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has been finalized.
B. Divestitures
Animal Health Business Zoetis Inc.
On June 24, 2013, we completed the full disposition of our Animal Health business (Zoetis). The full disposition was completed through a series of steps, including the formation of Zoetis, an initial public offering (IPO) of an approximate 19.8% interest in Zoetis and an exchange offer for the remaining 80.2% interest.
Formation of Zoetis On January 28, 2013, our then wholly owned subsidiary, Zoetis, issued $3.65 billion aggregate principal amount of senior notes. Also, on January 28, 2013, we transferred to Zoetis substantially all of the assets and liabilities of our Animal Health business in exchange for all of the Class A and Class B common stock of Zoetis, $1.0 billion of the $3.65 billion of Zoetis senior notes, and an amount of cash equal to substantially all of the cash proceeds received by Zoetis from the remaining $2.65 billion of senior notes issued. The $1.0 billion of Zoetis senior notes received by Pfizer were exchanged by Pfizer for the retirement of Pfizer commercial paper issued in 2012, and the cash proceeds received by Pfizer of approximately $2.6 billion were used for dividends and stock buybacks.
Initial Public Offering (19.8% Interest) On February 6, 2013, an IPO of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis (all of the Class A common stock, including shares sold pursuant to the underwriters' overallotment option to purchase additional shares, which was exercised in full) in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued in 2013. The Class A common stock sold in the IPO represented approximately 19.8% of the total outstanding Zoetis shares. The excess of the
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
consideration received over the net book value of our divested interest was approximately $2.3 billion and was recorded in Additional paid-in capital. For additional information, see Note 6. Certain Changes in Total Equity.
Exchange Offer (80.2% Interest) On June 24, 2013, we exchanged all of our remaining interest in Zoetis, 400.985 million shares of Class A common stock of Zoetis (after converting all of our Class B common stock into Class A common stock, representing approximately 80.2% of the total outstanding Zoetis shares), for approximately 405.117 million outstanding shares of Pfizer common stock on a tax-free basis pursuant to an exchange offer made to Pfizer shareholders. The $11.4 billion of Pfizer common stock received in the exchange transaction was recorded in Treasury stock and was valued using the opening price of Pfizer common stock on June 24, 2013, the date we accepted the Zoetis shares for exchange. For additional information, see Note 6. Certain Changes in Total Equity. The gain on the sale of the remaining interest in Zoetis was approximately $10.4 billion, net of income taxes resulting from certain legal entity reorganizations, and was recorded in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended June 30, 2013.
In summary, as a result of the above transactions, we received approximately $6.1 billion of cash and Treasury stock valued at $11.4 billion.
The operating results of the animal health business are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. In addition, in the condensed consolidated balance sheet as of December 31, 2012, the assets and liabilities associated with this business are classified as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate. Prior period financial statements have been restated.
In connection with the above transactions, we entered into a transitional services agreement (TSA) and manufacturing and supply agreements (MSAs) with Zoetis that are designed to facilitate the orderly transfer of business operations to the standalone Zoetis entity. The TSA relates primarily to administrative services, which are generally to be provided within 24 months. Under the MSAs, we will manufacture and supply certain animal health products to Zoetis for a transitional period of up to 5 years, with an ability to extend, if necessary, upon mutual agreement of both parties. These agreements are not material and none confers upon us the ability to influence the operating and/or financial policies of Zoetis subsequent to June 24, 2013, the full disposition date.
Nutrition Business
On November 30, 2012, we completed the sale of our Nutrition business to Nestl for $11.85 billion in cash, and recognized a gain of approximately $4.8 billion, net of tax. The divested business includes:
our former Nutrition operating segment and certain prenatal vitamins previously commercialized by the Pfizer Consumer Healthcare operating segment; and
other associated amounts, such as direct manufacturing costs, enabling support functions and other costs not charged to the business, purchase-accounting impacts, acquisition-related costs, impairment charges, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives, all of which are reported outside our operating segment results.
The operating results of this business are classified as Income from discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended July 1, 2012.
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table provides the components of Discontinued operations net of tax:
Three Months Ended(a)
Six Months Ended(a)
(MILLIONS OF DOLLARS)
June 30,
2013
July 1,
2012
June 30,
2013
July 1,
2012
Revenues
1,112
1,675
2,201
3,230
Pre-tax income from discontinued operations
189
422
389
796
Provision for taxes on income(b)
48
162
99
287
Income from discontinued operations net of tax
141
260
290
509
Pre-tax gain on disposal of discontinued operations
10,539
10,539
Provision for taxes on income(c)
121
121
Gain on disposal of discontinued operations net of tax
10,418
10,418
Discontinued operations net of tax
10,559
260
10,708
509
(a)
Includes the Animal Health (Zoetis) business for all periods presented and the Nutrition business for the three and six months ended July 1, 2012.
(b)
Includes a deferred tax benefit of $26 million and a deferred tax expense of $41 million for the three months ended June 30, 2013 and July 1, 2012, respectively, and a deferred tax benefit of $19 million and a deferred tax expense of $20 million for the six months ended June 30, 2013 and July 1, 2012, respectively. These deferred tax provisions include deferred taxes related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries indefinitely.
(c)
Reflects income taxes resulting from certain legal entity reorganizations.
The following table provides the components of Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations:
(MILLIONS OF DOLLARS)
June 30,
2013
December 31,
2012
Accounts receivable, less allowance for doubtful accounts
922
Inventories
1,137
Other current assets
550
Property, plant and equipment, less accumulated depreciation
100
1,318
Goodwill
1,011
Identifiable intangible assets, less accumulated amortization
867
Other noncurrent assets
139
Assets of discontinued operations and other assets held for sale
100
5,944
Current liabilities
874
Other liabilities
21
568
Liabilities of discontinued operations
21
1,442
The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for the six months ended June 30, 2013 and July 1, 2012.
C. Collaborative Arrangement
Collaboration for ertugliflozin
On April 29, 2013, we announced that we had entered into a worldwide, except Japan, collaboration agreement with Merck & Co., Inc. (Merck) for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Under the terms of the agreement, we will collaborate with Merck on the clinical development and commercialization of ertugliflozin, and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets. Merck will continue to retain the rights to its existing portfolio of sitagliptin-containing products. Through June 30, 2013, we received payments totaling $60 million and we will be eligible for additional payments associated with the achievement of future clinical, regulatory and
10
Table of Contents
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
commercial milestones. The payments received to date have been deferred and will be recognized in Other (income)/deductions net over a multi-year period. We will share potential revenues and certain costs with Merck on a 60%/40% basis, with Pfizer having the 40% share. Each party has the right to terminate the agreement at certain times under certain circumstances, with various resulting rights and obligations depending on the nature of the termination. In addition, Merck has the right to terminate the agreement at any time up to the commencement of the first Phase III clinical trial.
D. Equity-Method Investment
Investment in Hisun Pfizer Pharmaceuticals Company Limited
On September 6, 2012, we and Zhejiang Hisun Pharmaceuticals Co., Ltd., a leading pharmaceutical company in China, formed a new company, Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer), to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of $250 million, of which our portion was $122.5 million. On January 1, 2013, both parties transferred selected employees to Hisun Pfizer and contributed, among other things, certain rights to commercialized products and products in development, intellectual property rights, and facilities, equipment and distribution/customer contracts. Our contributions in 2013 constituted a business, as defined by U.S. GAAP, and included, among other things, the China rights to certain commercialized products and other products not yet commercialized and all associated intellectual property rights. As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious disease, oncology, mental health, and other therapeutic areas. We hold a 49% equity interest in Hisun Pfizer.
We also entered into certain transition agreements designed to ensure and facilitate the orderly transfer of the business operations to Hisun Pfizer, primarily the Pfizer Products Transition Period Agreement and a related supply and promotional services agreement. These agreements provide for a profit margin on the manufacturing services provided by Pfizer to Hisun Pfizer and govern the supply, promotion and distribution of Pfizer products until Hisun Pfizer begins its own manufacturing and distribution. While intended to be transitional, these agreements may be extended by mutual agreement of the parties for several years and, possibly, indefinitely. These agreements are not material to Pfizer, and none confers upon us any additional ability to influence the operating and/or financial policies of Hisun Pfizer.
In connection with our contributions in the first quarter of 2013, we recognized a pre-tax gain of approximately $459 million in Other (income)/deductions net, reflecting the transfer of the business to Hisun Pfizer (including an allocation of goodwill from our Emerging Markets reporting unit as part of the carrying amount of the business transferred). Since we hold a 49% interest in Hisun Pfizer, we have an indirect retained interest in the contributed assets; as such, 49% of the gain, or $225 million, represents the portion of the gain associated with that indirect retained interest.
In valuing our investment in Hisun Pfizer (which includes the indirect retained interest in the contributed assets), we used discounted cash flow techniques, utilizing a 11.5% discount rate, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.
We are accounting for our interest in Hisun Pfizer as an equity-method investment, due to the significant influence we have over the operations of Hisun Pfizer through our board representation, minority veto rights and 49% voting interest. Our investment in Hisun Pfizer is reported as a private equity investment in Long-term investments, and our share of Hisun Pfizer's income and expenses is recorded in Other (income)/deductions net. As of June 30, 2013, the carrying value of our investment in Hisun Pfizer is approximately $1.4 billion, and the amount of our underlying equity in the net assets of Hisun Pfizer is approximately $700 million. The excess of the carrying value of our investment over our underlying equity in the net assets of Hisun Pfizer has been allocated, within the investment account, to goodwill and other intangible assets. The amount allocated to other intangible assets is being amortized into Other (income)/deductions net over an average estimated useful life of 25 years.